Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: May 25, 2017

DrugPatentWatch Database Preview

Bupivacaine - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for bupivacaine and what is the scope of bupivacaine patent protection?

is the generic ingredient in thirteen branded drugs marketed by Pacira Pharms Inc, Fresenius Kabi Usa, Sagent Agila, Hospira, Intl Medicated, Claris, Aurobindo Pharma Ltd, Septodont, and Amphastar Pharms Inc, and is included in thirty-eight NDAs. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Bupivacaine has forty patent family members in sixteen countries.

There are ten drug master file entries for bupivacaine. One supplier is listed for this compound.

Summary for Generic Name: bupivacaine

Drug Master File Entries: see list10
Suppliers / Packagers: see list1
Bulk Api Vendors: see list62
Clinical Trials: see list369
Patent Applications: see list10,746
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:bupivacaine at DailyMed

Pharmacology for Ingredient: bupivacaine

Drug ClassAmide Local Anesthetic
Physiological EffectLocal Anesthesia
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fresenius Kabi Usa
bupivacaine hydrochloride
INJECTABLE;INJECTION018304-003Approved Prior to Jan 1, 1982APRXNoNo► Subscribe► Subscribe
Pacira Pharms Inc
INJECTABLE, LIPOSOMAL;INJECTION022496-002Oct 28, 2011RXYesYes8,834,921► SubscribeY ► Subscribe
bupivacaine hydrochloride
INJECTABLE;INJECTION016964-009Approved Prior to Jan 1, 1982APRXYesYes► Subscribe► Subscribe
bupivacaine hydrochloride
INJECTABLE;INJECTION070585-001Mar 3, 1987APRXNoNo► Subscribe► Subscribe
Amphastar Pharms Inc
bupivacaine hydrochloride; lidocaine hydrochloride
INJECTABLE;INJECTION021496-001May 23, 2003DISCNNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in abandoned patent applications and expired patents

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus